- Home
- INBS vs GLMD Comparison
INBS vs GLMD Comparison
Compare INBS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- GLMD
- Stock Information
- Founded
- INBS 2016
- GLMD 2000
- Country
- INBS United States
- GLMD Israel
- Employees
- INBS N/A
- GLMD N/A
- Industry
- INBS Medical Specialities
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- INBS Health Care
- GLMD Health Care
- Exchange
- INBS Nasdaq
- GLMD Nasdaq
- Market Cap
- INBS 9.6M
- GLMD 8.0M
- IPO Year
- INBS N/A
- GLMD 2014
- Fundamental
- Price
- INBS $1.01
- GLMD $1.35
- Analyst Decision
- INBS
- GLMD Hold
- Analyst Count
- INBS 0
- GLMD 1
- Target Price
- INBS N/A
- GLMD N/A
- AVG Volume (30 Days)
- INBS 376.2K
- GLMD 78.9K
- Earning Date
- INBS 11-07-2025
- GLMD 11-14-2025
- Dividend Yield
- INBS N/A
- GLMD N/A
- EPS Growth
- INBS N/A
- GLMD N/A
- EPS
- INBS N/A
- GLMD N/A
- Revenue
- INBS $3,052,532.00
- GLMD N/A
- Revenue This Year
- INBS $778.48
- GLMD N/A
- Revenue Next Year
- INBS N/A
- GLMD N/A
- P/E Ratio
- INBS N/A
- GLMD N/A
- Revenue Growth
- INBS N/A
- GLMD N/A
- 52 Week Low
- INBS $0.92
- GLMD $1.15
- 52 Week High
- INBS $2.75
- GLMD $3.90
- Technical
- Relative Strength Index (RSI)
- INBS 41.15
- GLMD 43.27
- Support Level
- INBS $0.92
- GLMD $1.30
- Resistance Level
- INBS $1.06
- GLMD $1.53
- Average True Range (ATR)
- INBS 0.06
- GLMD 0.08
- MACD
- INBS 0.01
- GLMD -0.01
- Stochastic Oscillator
- INBS 42.86
- GLMD 22.52
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.